Tandem Diabetes Care (BSP:T2ND34) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:T2ND34 Tandem Diabetes Care Inc BSP:T2ND34
49 GF Score
Price R$5.98
GF Value R$8.36
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Tandem Diabetes Care  (BSP:T2ND34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Tandem Diabetes Care Cyclically Adjusted PS Ratio Related Terms


Tandem Diabetes Care Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Tandem Diabetes Care's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tandem Diabetes Care Cyclically Adjusted PS Ratio Chart

Tandem Diabetes Care Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Tandem Diabetes Care Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.89

BSP:T2ND34 vs CNMD, ATEC, ENOV: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, Tandem Diabetes Care's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tandem Diabetes Care Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's Cyclically Adjusted PS Ratio falls into.


BSP:T2ND34
49GF Score
Tandem Diabetes Care Inc BSP:T2ND34
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tandem Diabetes Care Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Tandem Diabetes Care's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Tandem Diabetes Care's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.239/333.9520*333.9520
=1.239

Current CPI (Jun. 2026) = 333.9520.

Tandem Diabetes Care Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.867 241.428 1.199
201612 2.057 241.432 2.845
201703 12.457 243.801 17.063
201706 0.912 244.955 1.243
201709 1.098 246.819 1.486
201712 0.941 246.524 1.275
201803 0.328 249.554 0.439
201806 0.161 251.989 0.213
201809 0.219 252.439 0.290
201812 0.317 251.233 0.421
201903 0.287 254.202 0.377
201906 0.418 256.143 0.545
201909 0.425 256.759 0.553
201912 0.473 256.974 0.615
202003 0.487 258.115 0.630
202006 0.647 257.797 0.838
202009 0.720 260.280 0.924
202012 0.920 260.474 1.180
202103 0.824 264.877 1.039
202106 0.926 271.696 1.138
202109 0.965 274.310 1.175
202112 1.185 278.802 1.419
202203 0.959 287.504 1.114
202206 1.025 296.311 1.155
202209 1.112 296.808 1.251
202212 1.199 296.797 1.349
202303 0.907 301.836 1.004
202306 0.997 305.109 1.091
202309 0.927 307.789 1.006
202312 0.994 306.746 1.082
202403 0.968 312.332 1.035
202406 1.185 314.175 1.260
202409 1.375 315.301 1.456
202412 1.661 315.605 1.758
202503 1.375 319.799 1.436
202506 1.355 322.561 1.403
202509 1.337 324.800 1.375
202512 1.534 324.054 1.581
202603 1.266 330.213 1.280
202606 1.239 333.952 1.239

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Tandem Diabetes Care (BSP:T2ND34) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of R$5.98 is trading 28.5% below its estimated GF Value™ of R$8.36. GuruFocus considers Tandem Diabetes Care to be Modestly Undervalued.

Key valuation signals for BSP:T2ND34:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: R$8.36 vs. price of R$5.98 (28.5% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the BSP:T2ND34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tandem Diabetes Care Business Description

Other Exchanges TNDM:USA0M0F:UKTD5A:Germany
Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
49GF Score

Get the complete analysis for BSP:T2ND34

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$5.98
Price
R$8.36
GF Value